Progressive Supranuclear Palsy Epidemiology Forecast

DelveInsight’s ‘Progressive Supranuclear Palsy - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Progressive Supranuclear Palsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Progressive Supranuclear Palsy: Understanding

The DelveInsight’s Progressive Supranuclear Palsy epidemiology report gives a thorough understanding of Progressive Supranuclear Palsy by including details such as disease classification, etiology, pathophysiology, and diagnosis. It also provides a treatment algorithm for Progressive Supranuclear Palsy. Moreover, the report covers detailed information on the Progressive Supranuclear Palsy epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight:

This section encompassing Progressive Supranuclear Palsy epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The Progressive Supranuclear Palsy epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The Progressive Supranuclear Palsy epidemiology covered in the report provides historical as well as forecasted Progressive Supranuclear Palsy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.


The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Progressive Supranuclear Palsy report covers a detailed overview explaining its etiology, pathophysiology classification, diagnosis, and treatment patterns.
  • The Progressive Supranuclear Palsy report and model provide an overview of the global trends of Progressive Supranuclear Palsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Progressive Supranuclear Palsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Progressive Supranuclear Palsy.
  • The report provides the segmentation of the Progressive Supranuclear Palsy epidemiology

Report Highlights:

  • 11-year Forecast of Progressive Supranuclear Palsy Epidemiology
  • 7MM Coverage
  • Prevalence of PSP,
  • Phenotype associated with PSP
  • Gender-specific prevalence of PSP
  • Comorbidities associated with PSP

KOL Views:

We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered:

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Progressive Supranuclear Palsy?
  • What are the key findings pertaining to the Progressive Supranuclear Palsy epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017–2030)?
  • What would be the total number of patients of Progressive Supranuclear Palsy across the 7MM during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
  • What are the disease risk, burden, and unmet needs of Progressive Supranuclear Palsy?
  • What are the currently available treatments of Progressive Supranuclear Palsy?

Reasons to buy:

The Progressive Supranuclear Palsy Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Progressive Supranuclear Palsy market.
  • Quantify patient populations in the global Progressive Supranuclear Palsy market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Progressive Supranuclear Palsy therapeutics in each of the markets covered
  • Understand the magnitude of Progressive Supranuclear Palsy population by its epidemiology
  • The Progressive Supranuclear Palsy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments:

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

 

1 Key Insights

2 Executive Summary of Progressive Supranuclear Palsy

3 SWOT Analysis for Progressive Supranuclear Palsy

4 Progressive Supranuclear Palsy (PSP) Epidemiology Overview at a Glance

4.1 Epidemiology of Progressive Supranuclear Palsy (PSP) in 2017

4.2 Epidemiology of Progressive Supranuclear Palsy (PSP) in 2030

5 Disease Background and Overview: Progressive Supranuclear Palsy (PSP)

5.1 Introduction

5.2 Signs and symptoms

5.3 Phenotypes of Progressive Supranuclear Palsy

5.4 History

5.5 Associated risk factors

5.6 Genetics

5.7 Pathophysiology

5.8 PSP associated abnormalities

5.9 Clinical Presentation and Assessment

5.10 Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria

5.11 PET Imaging as a Biomarker in Tauopathies

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Patient Population of Progressive Supranuclear Palsy [PSP]

7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)

7.1 The United States

7.1.1 Assumptions and Rationale

7.1.2 Total Prevalent Patient Population of PSP in the United States

7.1.3 Phenotype associated with PSP in the United States

7.1.4 Gender specific Prevalence of PSP in the United States

7.1.5 Comorbidities associated with PSP in the United States

7.2 Europe

7.2.1 Assumptions and Rationale

7.2.2 Germany

7.2.2.1 Total Prevalent Patient Population of PSP in Germany

7.2.2.2 Phenotype associated with PSP in Germany

7.2.2.3 Gender specific Prevalence of PSP in Germany

7.2.2.4 Comorbidities associated with PSP in Germany

7.2.3 France

7.2.3.1 Total Prevalent Patient Population of PSP in France

7.2.3.2 Phenotype associated with PSP in France

7.2.3.3 Gender specific Prevalence of PSP in France

7.2.3.4 Comorbidities associated with PSP in France

7.2.4 Italy

7.2.4.1 Total Prevalent Patient Population of PSP in Italy

7.2.4.2 Phenotype associated with PSP in Italy

7.2.4.3 Gender specific Prevalence of PSP in Italy

7.2.4.4 Comorbidities associated with PSP in Italy

7.2.5 Spain

7.2.5.1 Total Prevalent Patient Population of PSP in Spain

7.2.5.2 Phenotype associated with PSP in Spain

7.2.5.3 Gender specific Prevalence of PSP in Spain

7.2.5.4 Comorbidities associated with PSP in Spain

7.2.6 The United Kingdom

7.2.6.1 Total Prevalent Patient Population of PSP in the United Kingdom

7.2.6.2 Phenotype associated with PSP in the United Kingdom

7.2.6.3 Gender specific Prevalence of PSP in the United Kingdom

7.2.6.4 Comorbidities associated with PSP in the United Kingdom

7.3 Japan

7.3.1 Assumptions and Rationale

7.3.2 Total Prevalent Patient Population of PSP in Japan

7.3.3 Phenotype associated with PSP in Japan

7.3.4 Gender specific Prevalence of PSP in Japan

7.3.5 Comorbidities associated with PSP in Japan

8 Treatment

8.1 Current symptomatic treatment

9 Unmet Needs

10 Appendix

10.1 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Table

Table 1: Summary of Progressive Supranuclear Palsy (PSP) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Core clinical features

Table 3: Supportive Features

Table 4: Diagnostic criteria for PSP

Table 5: Total Prevalent Patient Population of PSP in 7MM (2017–2030)

Table 6: Total Prevalent Population of PSP in the United States (2017–2030)

Table 7: Phenotype associated with PSP in the United States (2017–2030)

Table 8: Gender specific Prevalence of PSP in the United States (2017–2030)

Table 9: Comorbidities associated with PSP in the United States (2017–2030)

Table 10: Total Prevalent Population of PSP in Germany (2017–2030)

Table 11: Phenotype associated with PSP in Germany (2017–2030)

Table 12: Gender specific Prevalence of PSP in Germany (2017–2030)

Table 13: Comorbidities associated with PSP in Germany (2017–2030)

Table 14: Total Prevalent Population of PSP in France (2017–2030)

Table 15: Phenotype associated with PSP in France (2017–2030)

Table 16: Gender specific Prevalence of PSP in France (2017–2030)

Table 17: Comorbidities associated with PSP in France (2017–2030)

Table 18: Total Prevalent Population of PSP in Italy (2017–2030)

Table 19: Phenotype associated with PSP in Italy (2017–2030)

Table 20: Gender specific Prevalence of PSP in Italy (2017–2030)

Table 21: Comorbidities associated with PSP in Italy (2017–2030)

Table 22: Total Prevalent Population of PSP in Spain (2017–2030)

Table 23: Phenotype associated with PSP in Spain (2017–2030)

Table 24: Gender specific Prevalence of PSP in Spain (2017–2030)

Table 25: Comorbidities associated with PSP in Spain (2017–2030)

Table 26: Total Prevalent Population of PSP in the United Kingdom (2017–2030)

Table 27: Phenotype associated with PSP in the United Kingdom (2017–2030)

Table 28: Gender specific Prevalence of PSP in the United Kingdom (2017–2030)

Table 29: Comorbidities associated with PSP in the United Kingdom (2017–2030)

Table 30: Total Prevalent Population of PSP in Japan (2017–2030)

Table 31: Phenotype associated with PSP in Japan (2017–2030)

Table 32: Gender specific Prevalence of PSP in Japan (2017–2030)

Table 33: Comorbidities associated with PSP in Japan (2017–2030)

List of Figures

Figure 1: SWOT Analysis

Figure 2: Tau isoforms and conformations

Figure 3: Tau hyperphosphorylation and aggregation

Figure 4: Total Prevalent Patient Population of PSP in 7MM (2017–2030)

Figure 5: Prevalence of PSP in the United States (2017–2030)

Figure 6: Phenotype associated with PSP in the United States (2017–2030)

Figure 7: Gender specific Prevalence of PSP in the United States (2017–2030)

Figure 8: Comorbidities associated with PSP in the United States (2017–2030)

Figure 9: Prevalence of PSP in Germany (2017–2030)

Figure 10: Phenotype associated with PSP in Germany (2017–2030)

Figure 11: Gender specific Prevalence of PSP in Germany (2017–2030)

Figure 12: Comorbidities associated with PSP in Germany (2017–2030)

Figure 13: Prevalence of PSP in France (2017–2030)

Figure 14: Phenotype associated with PSP in France (2017–2030)

Figure 15: Gender specific Prevalence of PSP in France (2017–2030)

Figure 16: Comorbidities associated with PSP in France (2017–2030)

Figure 17: Prevalence of PSP in Italy (2017–2030)

Figure 18: Phenotype associated with PSP in Italy (2017–2030)

Figure 19: Gender specific Prevalence of PSP in Italy (2017–2030)

Figure 20: Comorbidities associated with PSP in Italy (2017–2030)

Figure 21: Prevalence of PSP in Spain (2017–2030)

Figure 22: Phenotype associated with PSP in Spain (2017–2030)

Figure 23: Gender specific Prevalence of PSP in Spain (2017–2030)

Figure 24: Comorbidities associated with PSP in Spain (2017–2030)

Figure 25: Prevalence of PSP in the United Kingdom (2017–2030)

Figure 26: Phenotype associated with PSP in the United Kingdom (2017–2030)

Figure 27: Gender specific Prevalence of PSP in the United Kingdom (2017–2030)

Figure 28: Comorbidities associated with PSP in the United Kingdom (2017–2030)

Figure 29: Prevalence of PSP in Japan (2017–2030)

Figure 30: Phenotype associated with PSP in Japan (2017–2030)

Figure 31: Gender specific Prevalence of PSP in Japan (2017–2030)

Figure 32: Comorbidities associated with PSP in Japan (2017–2030)

Figure 33: Potential therapeutic targets for progressive supranuclear palsy

Figure 34: Potential therapeutic targets for progressive suparnuclear palsy

Figure 35: Unmet Needs of PSP

  • Tags:
  • Progressive Supranuclear Palsy Epid...
  • Progressive Supranuclear Palsy
  • Progressive Supranuclear Palsy Pip...
  • Progressive Supranuclear Palsy Com...
  • Progressive Supranuclear Palsy pre...
  • Progressive Supranuclear Palsy inc...
  • Progressive Supranuclear Palsy pat...
  • Progressive Supranuclear Palsy tre...

Forward to Friend

Need A Quote